Short description
Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies.
Description
Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products; its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
Last funding
Absolutely Noaccess
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
New York, New York, United States, North America
Founded on
April 1, 2016
Exited on
April 15, 2019
Went public on
April 15, 2019
Stock symbol
IMUX
Non-profit?
No
Acquired?
No
Employees count
51-100
Revenue range
$1230 - 4560
Sign in for full access
Investors
Noaccess, Noway Youcantaccess, Noaccess, Noaccess, Noway Youcantaccess, Cannot Access, Blurry Noaccess, Uh Ohhhh, Blurry Noaccess, Noaccess, Noaccess, Noaccess, Absolutely Noaccess, Noway Youcantaccess, Noaccess, Nopepepe, Noway Youcantaccess, Noaccess, Noaccess, Absolutely Noaccess, Uh Ohhhh, Noway Youcantaccess, Blurry Noaccess, Noaccess
Sign in for full access
Founders
Andreas Muehler